KRKG Stock Overview
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally.
Krka d. d Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€116.50|
|52 Week High||€121.00|
|52 Week Low||€88.20|
|1 Month Change||4.96%|
|3 Month Change||4.48%|
|1 Year Change||31.79%|
|3 Year Change||110.29%|
|5 Year Change||115.74%|
|Change since IPO||1,368.83%|
Recent News & Updates
Are Investors Undervaluing Krka, d. d. (LJSE:KRKG) By 49%?
Does the November share price for Krka, d. d. ( LJSE:KRKG ) reflect what it's really worth? Today, we will estimate the...
Here's Why We Think Krka d. d (LJSE:KRKG) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Are Investors Undervaluing Krka, d. d. (LJSE:KRKG) By 49%?
Does the August share price for Krka, d. d. ( LJSE:KRKG ) reflect what it's really worth? Today, we will estimate the...
|KRKG||SI Pharmaceuticals||SI Market|
Return vs Industry: KRKG exceeded the SI Pharmaceuticals industry which returned 16.8% over the past year.
Return vs Market: KRKG underperformed the SI Market which returned 38.8% over the past year.
|KRKG Average Weekly Movement||2.8%|
|Pharmaceuticals Industry Average Movement||5.4%|
|Market Average Movement||2.7%|
|10% most volatile stocks in SI Market||6.0%|
|10% least volatile stocks in SI Market||2.4%|
Stable Share Price: KRKG is not significantly more volatile than the rest of SI stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: KRKG's weekly volatility (3%) has been stable over the past year.
About the Company
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. Its prescription pharmaceuticals include medicines for the treatment of cardiovascular diseases; the gastrointestinal tract; central nervous system; pain relief; anti-infectives; blood and blood-forming organs; urological; diabetes; and oncology. The company also provides non-prescription products, such as products for oral cavity and pharynx; cough and cold products; analgesics; nasal products; vitamin and mineral products; products for enhancing cerebral and peripheral circulation; products for enhancing digestive tract and digestion; health care products; and others.
Krka d. d Fundamentals Summary
|KRKG fundamental statistics|
Is KRKG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|KRKG income statement (TTM)|
|Cost of Revenue||€676.85m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Jan 27, 2022
|Earnings per share (EPS)||10.28|
|Net Profit Margin||20.64%|
How did KRKG perform over the long term?See historical performance and comparison
4.3%Current Dividend Yield
Is Krka d. d undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: KRKG (€116.5) is trading below our estimate of fair value (€235.85)
Significantly Below Fair Value: KRKG is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: KRKG is good value based on its PE Ratio (11.3x) compared to the European Pharmaceuticals industry average (27.1x).
PE vs Market: KRKG is poor value based on its PE Ratio (11.3x) compared to the SI market (10x).
Price to Earnings Growth Ratio
PEG Ratio: KRKG's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: KRKG is good value based on its PB Ratio (2x) compared to the XE Pharmaceuticals industry average (3.1x).
How is Krka d. d forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KRKG's earnings are forecast to decline over the next 3 years (-0.6% per year).
Earnings vs Market: KRKG's earnings are forecast to decline over the next 3 years (-0.6% per year).
High Growth Earnings: KRKG's earnings are forecast to decline over the next 3 years.
Revenue vs Market: KRKG's revenue (2.1% per year) is forecast to grow slower than the SI market (2.9% per year).
High Growth Revenue: KRKG's revenue (2.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: KRKG's Return on Equity is forecast to be low in 3 years time (12.4%).
How has Krka d. d performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KRKG has high quality earnings.
Growing Profit Margin: KRKG's current net profit margins (20.6%) are higher than last year (18.2%).
Past Earnings Growth Analysis
Earnings Trend: KRKG's earnings have grown significantly by 22.2% per year over the past 5 years.
Accelerating Growth: KRKG's earnings growth over the past year (12.6%) is below its 5-year average (22.2% per year).
Earnings vs Industry: KRKG earnings growth over the past year (12.6%) underperformed the Pharmaceuticals industry 12.6%.
Return on Equity
High ROE: KRKG's Return on Equity (17.2%) is considered low.
How is Krka d. d's financial position?
Financial Position Analysis
Short Term Liabilities: KRKG's short term assets (€1.4B) exceed its short term liabilities (€320.1M).
Long Term Liabilities: KRKG's short term assets (€1.4B) exceed its long term liabilities (€173.0M).
Debt to Equity History and Analysis
Debt Level: KRKG is debt free.
Reducing Debt: KRKG had no debt 5 years ago.
Debt Coverage: KRKG has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: KRKG has no debt, therefore coverage of interest payments is not a concern.
What is Krka d. d current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: KRKG's dividend (4.29%) is higher than the bottom 25% of dividend payers in the SI market (3.67%).
High Dividend: KRKG's dividend (4.29%) is low compared to the top 25% of dividend payers in the SI market (4.88%).
Stability and Growth of Payments
Stable Dividend: KRKG's dividends per share have been stable in the past 10 years.
Growing Dividend: KRKG's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (48.7%), KRKG's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: KRKG's dividends in 3 years are forecast to be covered by earnings (62.1% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jože Colaric (66 yo)
Dr. Jože Colaric has been the Chief Executive Officer and President of the Management Board at KrKa dd Novo Mesto since January 1, 2005. Dr. Colaric has been Member of the Management Board at KrKa dd Novo...
CEO Compensation Analysis
Compensation vs Market: Jože's total compensation ($USD1.40M) is about average for companies of similar size in the SI market ($USD1.53M).
Compensation vs Earnings: Jože's compensation has been consistent with company performance over the past year.
Experienced Management: KRKG's management team is seasoned and experienced (10.8 years average tenure).
Experienced Board: KRKG's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Krka, d. d.'s employee growth, exchange listings and data sources
- Name: Krka, d. d.
- Ticker: KRKG
- Exchange: LJSE
- Founded: 1954
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €3.629b
- Shares outstanding: 31.15m
- Website: https://www.krka.biz
Number of Employees
- Krka, d. d.
- Šmarješka cesta 6
- Novo Mesto
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/01 22:00|
|End of Day Share Price||2021/12/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.